Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Lee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    Menu

    Eptinezumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lundbeck Shows Vyepti Long-Term Migraine Prevention Efficacy
    Lundbeck Shows Vyepti Long-Term Migraine Prevention Efficacy

    11 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lundbeck-showcases-new-clinical-migraine-data-including-long-term-preventive-effectiveness-of-vyepti-eptinezumab-in-patients-severely-impacted-by-migraine-302553629.html

    PR NEWSWIRE
    11 Sep 2025
    Share Share
    Lundbeck to Present Broad Range of Data on Migraine at 75th Annual Meeting
    Lundbeck to Present Broad Range of Data on Migraine at 75th Annual Meeting

    17 Apr 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230417005030/en

    BUSINESSWIRE
    17 Apr 2023
    Share Share
    Lundbeck's Biologic Vyepti (Eptinezumab) Receives Approval in the U.S.
    Lundbeck's Biologic Vyepti (Eptinezumab) Receives Approval in the U.S.

    21 Oct 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761119

    FDA
    21 Oct 2022
    Share Share
    Setback at Lundbeck: CGRP migraine drug Vyepti hits trial snag
    Setback at Lundbeck: CGRP migraine drug Vyepti hits trial snag

    19 Aug 2022

    // Angus Liu FIERCEPHARMA

    https://www.fiercepharma.com/pharma/setback-lundbeck-cgrp-migraine-drug-vyepti-hits-expansion-snag-sales-still-doubled

    Angus Liu FIERCEPHARMA
    19 Aug 2022
    Share Share
    Lundbeck to Present Data on VYEPTI at the Annual Meeting of AHS for Migraine
    Lundbeck to Present Data on VYEPTI at the Annual Meeting of AHS for Migraine

    09 Jun 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220609005304/en

    BUSINESSWIRE
    09 Jun 2022
    Share Share
    Lundbeck's Vyepti (Eptinezumab) Receives Approval in Europe
    Lundbeck's Vyepti (Eptinezumab) Receives Approval in Europe

    15 Feb 2022

    // EMA

    https://www.ema.europa.eu/en/medicines/human/EPAR/vyepti

    EMA
    15 Feb 2022
    Share Share